Table 2.
Use of basal and bolus insulin in the SWITCH 1 and SWITCH 2 trials
| Treatment group | Observed glargine U100 (units/day) | Dose ratio (degludec/glargine U100) [95% CI] |
Calculated degludec (units/day) |
|---|---|---|---|
| SWITCH 1: T1DMB/B | |||
| Total dose (U) | 0.97 [0.95; 0.99] | ||
| Basal insulin (U) | 40.58 | 0.97 [0.95; 0.99] | 39.36a |
| Bolus insulin (U) | 31.93 | 0.97 [0.94; 1.01] (NS) | 31.93 |
| SWITCH 2: T2DMBOT | |||
| Total dose (U) | 0.96 [0.94; 0.98] | ||
| Basal insulin (U) | 82.66 | 0.96 [0.94; 0.98] | 79.35 |
| Bolus insulin (U) | N/A | N/A | N/A |
aObserved glargine U100 units/day × dose ratio
A dose ratio of 1.0 was used when the difference was not statistically significant
B/B basal–bolus therapy, BOT basal-only therapy, CI confidence interval, glargine U100 insulin glargine 100 units/mL, N/A not applicable, NS not significant, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus